Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1954 6
1955 5
1956 4
1957 1
1959 1
1960 1
1962 1
1964 2
1965 6
1966 11
1967 6
1968 5
1969 11
1970 9
1971 11
1972 6
1973 11
1974 6
1975 11
1976 18
1977 12
1978 4
1979 7
1980 13
1981 10
1982 5
1983 9
1984 9
1985 8
1986 9
1987 9
1988 15
1989 6
1990 18
1991 12
1992 12
1993 17
1994 13
1995 8
1996 10
1997 13
1998 19
1999 19
2000 15
2001 20
2002 20
2003 20
2004 18
2005 15
2006 29
2007 32
2008 30
2009 23
2010 25
2011 28
2012 34
2013 33
2014 28
2015 22
2016 30
2017 42
2018 40
2019 39
2020 44
2021 64
2022 50
2023 58
2024 57
2025 77
2026 32

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,241 results

Results by year

Filters applied: . Clear all
Page 1
Treatment of myasthenia gravis: focus on pyridostigmine.
Maggi L, Mantegazza R. Maggi L, et al. Clin Drug Investig. 2011 Oct 1;31(10):691-701. doi: 10.2165/11593300-000000000-00000. Clin Drug Investig. 2011. PMID: 21815707 Review.
Acquired myasthenia gravis (MG) is a chronic autoimmune disorder of the neuromuscular junction, characterized clinically by muscle weakness and abnormal fatigability on exertion. ...Pyridostigmine has been used as a treatment for MG for over 50 years and is g …
Acquired myasthenia gravis (MG) is a chronic autoimmune disorder of the neuromuscular junction, characterized clinically by mu …
The effectiveness and side effects of pyridostigmine in the treatment of myasthenia gravis: a cross-sectional study.
Remijn-Nelissen L, Verschuuren JJGM, Tannemaat MR. Remijn-Nelissen L, et al. Neuromuscul Disord. 2022 Oct;32(10):790-799. doi: 10.1016/j.nmd.2022.09.002. Epub 2022 Sep 7. Neuromuscul Disord. 2022. PMID: 36184373 Free article.
Pyridostigmine is the most commonly used drug in the symptomatic treatment of myasthenia gravis (MG); however, research into its effectiveness and side effects is scarce. The aim of this study was to assess the effectiveness, prevalence of side effects and ne …
Pyridostigmine is the most commonly used drug in the symptomatic treatment of myasthenia gravis (MG); however, research …
Efficacy of Pyridostigmine in Myasthenia Gravis: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial.
Remijn-Nelissen L, Bakker WR, van den Hout WB, van Gelder T, Ruiter AM, Campman YJM, Badrising UA, Straathof CSM, Verschuuren JJGM, Tannemaat MR. Remijn-Nelissen L, et al. Neurology. 2026 Apr 28;106(8):e214865. doi: 10.1212/WNL.0000000000214865. Epub 2026 Apr 7. Neurology. 2026. PMID: 41945881 Clinical Trial.
Pyridostigmine dosing matched each participant's prestudy regimen. The primary outcome was change in the Myasthenia Gravis Impairment Index (MGII) score. Secondary efficacy outcome measures included the Myasthenia Gravis Activities of Daily Livi …
Pyridostigmine dosing matched each participant's prestudy regimen. The primary outcome was change in the Myasthenia Gravis …
Celebrating the 70 years of pyridostigmine on therapy of Myasthenia Gravis: historical aspects of the preliminary trials.
Lorenzoni PJ, Kay CSK, Ducci RD, Fustes OJH, Werneck LC, Scola RH. Lorenzoni PJ, et al. Arq Neuropsiquiatr. 2020 Mar;78(3):179-181. doi: 10.1590/0004-282X20190189. Epub 2020 Mar 16. Arq Neuropsiquiatr. 2020. PMID: 32215460 Free article. Review.
Currently, pyridostigmine bromide is an indispensable anticholinesterase agent used worldwide to treat patients with Myasthenia Gravis (MG). However, pyridostigmine bromide was unsuccessful in its "pioneering trials" to treat a series of …
Currently, pyridostigmine bromide is an indispensable anticholinesterase agent used worldwide to treat patients with Myasth …
Autoimmune myasthenia gravis.
Lopate G, Pestronk A. Lopate G, et al. Hosp Pract (Off Ed). 1993 Jan 15;28(1):109-12, 115-7, 121-2, passim. doi: 10.1080/21548331.1993.11442741. Hosp Pract (Off Ed). 1993. PMID: 8380423 Review.
Pyridostigmine Suicidal Attempt in a Myasthenia Gravis Patient.
Malabaey MAT, Al-Saud AA, Alaska YA, Almas A, Malik A. Malabaey MAT, et al. Am J Case Rep. 2019 Sep 26;20:1418-1421. doi: 10.12659/AJCR.917308. Am J Case Rep. 2019. PMID: 31554781 Free PMC article.
BACKGROUND Pyridostigmine is a quaternary amine parasympathomymetic which inhibits acetylcholinesterase for the treatment of various conditions such as myasthenia gravis. ...As the literature on human toxicity with pyridostigmine is scarce, not much da …
BACKGROUND Pyridostigmine is a quaternary amine parasympathomymetic which inhibits acetylcholinesterase for the treatment of various …
Myasthenia gravis crisis.
Bershad EM, Feen ES, Suarez JI. Bershad EM, et al. South Med J. 2008 Jan;101(1):63-9. doi: 10.1097/SMJ.0b013e31815d4398. South Med J. 2008. PMID: 18176295 Review.
Myasthenia gravis (MG) is an autoimmune disorder resulting from the production of antibodies against acetylcholine receptors leading to the destruction of the postsynaptic membrane at the neuromuscular junction. In the US there are about 18,000 people with MG. My …
Myasthenia gravis (MG) is an autoimmune disorder resulting from the production of antibodies against acetylcholine receptors l …
Anesthesia and myasthenia gravis.
Blichfeldt-Lauridsen L, Hansen BD. Blichfeldt-Lauridsen L, et al. Acta Anaesthesiol Scand. 2012 Jan;56(1):17-22. doi: 10.1111/j.1399-6576.2011.02558.x. Epub 2011 Oct 19. Acta Anaesthesiol Scand. 2012. PMID: 22091897 Review.
Myasthenia gravis (MG) is a disease affecting the nicotinic acetylcholine receptor of the post-synaptic membrane of the neuromuscular junction, causing muscle fatigue and weakness. ...The review is based on electronic searches on PubMed and a review of the reference …
Myasthenia gravis (MG) is a disease affecting the nicotinic acetylcholine receptor of the post-synaptic membrane of the neurom …
Quantification of Cover Test Prior and Post Pyridostigmine in Diagnosis of Myasthenia Gravis.
Saint-Gerons M, Rubio MA, Martinez A, Matheu A. Saint-Gerons M, et al. J Binocul Vis Ocul Motil. 2021 Apr-Jun;71(2):71-76. doi: 10.1080/2576117X.2021.1904097. Epub 2021 Apr 20. J Binocul Vis Ocul Motil. 2021. PMID: 33877951
Objective: To assess the value of measuring diplopia before and after pyridostigmine intake to differentiate myasthenia gravis from sagging eye syndrome.To establish a threshold for a positive response to pyridostigmine in the diagnosis of myastheni …
Objective: To assess the value of measuring diplopia before and after pyridostigmine intake to differentiate myasthenia gra …
Post-varicella myasthenia gravis.
Saha A, Batra P, Vilhekar KY, Chaturvedi P. Saha A, et al. Singapore Med J. 2007 Jun;48(6):e177-80. Singapore Med J. 2007. PMID: 17538742 Free article.
Myasthenia gravis is an autoimmune disease of neuromuscular junctions. We report a three-year-old boy with post-varicella myasthenia gravis. ...Repetitive nerve stimulation tests showed decremental response in action potential, and the child responded …
Myasthenia gravis is an autoimmune disease of neuromuscular junctions. We report a three-year-old boy with post-varicella m …
1,241 results